|
2005P-0417:
Determination of ANDAs for Tretinoin Cream in the Intermediate 0.0375%
and 0.075% Strengths
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Document #
|
| Received Date
|
| Filed
Date
|
| Submitter Code
|
| Submitter
|
| FR
Date
|
| FR
Page
|
| Comment Date
|
| Files
|
| Remarks
|
|
|
|
|
|
|
| CP1
|
| 10/18/2005
|
| 10/18/2005
|
| Drug Industry
|
| Triax Pharmaceuticals,
LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Keith S. Rotenberg, PhD
|
|
|
|
|
| ACK1
|
| 10/18/2005
|
| 10/18/2005
|
| Federal Government
|
| HFA-305 to Triax Pharmaceuticals,
LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Gloria Ortega
|
|
|
|
|
| SUP1
|
| 01/19/2006
|
| 01/18/2006
|
| Drug Industry
|
| Triax Pharmaceuticals,
LLC
|
|
|
|
|
|
|
| Table
of Contents
|
|
|
|
|
| Signature:
|
| Keith S. Rotenberg, PhD
|
|
|
|
|
| C1
|
| 02/16/2006
|
| 02/14/2006
|
| Drug Industry
|
| Johnson
& Johnson Consumer & Personal Products Worldwide (J&JCPPW)
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
|
|
|
|
| Signature:
|
| Stephanie J. Davis, RPh
|
|
|
|
|
|
| C2
|
| 03/17/2006
|
| 03/17/2006
|
| Individual Consumer
|
| D. Lowe
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| LET1
|
| 03/21/2006
|
| 03/21/2006
|
| Federal Government
|
| HFD-600 to Triax Pharmaceuticals,
LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
| |
|
|
|
| SUP2
|
| 01/08/2007
|
| 01/05/2007
|
| Drug Industry
|
| Triax Pharmaceuticals,
LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
| Signature:
|
| Keith S. Rotenberg, PhD
|
|
|
|
|
| PAV1
|
| 05/11/2007
|
| 05/11/2007
|
| Federal
Government
|
| FDA/CDER to Triax
Pharmaceuticals, LLC
|
|
|
|
|
|
|
| pdf
|
|
|
|
|
|
| Signature:
|
| Gary J. Buehler
|
|
|
|
|
|
|
|
|
|
|
| |
Top | Page last updated:
May 23, 2007
|
